Doxecitine and Doxribtimine: First Approval
Open Access
- 28 January 2026
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 28 (2) , 209-215
Abstract
Doxecitine and doxribtimine (KYGEVVI®) are pyrimidine nucleosides developed by UCB for the treatment of thymidine kinase 2 deficiency (TK2d). In November 2025, doxecitine and doxribtimine received its first approval in the USA for the treatment of TK2d in adult and pediatric patients with an age of symptom onset on or before 12 years. This article summarizes the milestones in the development of doxecitine and doxribtimine leading to this first approval for TK2d.Keywords
This publication has 7 references indexed in Scilit:
- 71PSafety of pyrimidine nucleos(t)ide therapy in Thymidine kinase 2 deficiency: an integrated analysis from a pooled datasetNeuromuscular Disorders, 2025
- Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 DeficiencyNeurology, 2025
- Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy AdultsClinical Therapeutics, 2024
- The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of lifeMitochondrion, 2022
- Retrospective natural history of thymidine kinase 2 deficiencyJournal of Medical Genetics, 2018
- Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 DeficiencyAnnals of Neurology, 2017
- Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic OptionsNeurotherapeutics, 2013